The Pharma Launch Blog

November 19, 2015

2015’s Most Notable Drug Launches to Follow

Why try to invent the wheel when you can get inspired by those who do it best- Here are some of the most successful pharma launches this year, worth following:

1. First place goes to 2 cholesterol-lowering drugs; one is Amgen’s Repatha, anticipated to generate $2.5 billion in sales by 2020, and the other is Sanofi’s Praluent, expected to garner $2.1 billion. Also first in sales is a cardiovascular product by Novartis, expected to reap $4.8 billion by 2020.

2. Coming in second is recently approved Pfizer’s Ibrance (for breast cancer), projected to rise former pharma giant Accolades from the ashes. In closed circles, this is actually referred to as one of the most successful drug launches in the history of Oncology’s drug market!

3. In the third place we have other players such as Vertex Pharmaceuticals’ Orkanbi for cyctic fibrosis expected to reach $3.4 billion; Merck & Co’s combined regimen of Elbasvir and Grazoprevir, reaching global sales of $1.9 billion; Sanofi’s Toujeo for diabetes is forecasted at $1.5 billion, while their Consentyx for psoriasis will secure $1.4 billion; Actelion’s Uptravi is estimated to reach $1.1 billion; and Alexion Pharmaceuticals’ Kanuma for LAL is expected to bring $748 million.

Original Article: http://verix.com/2015s-notable-drug-approvals/

Leave a Reply

Your email address will not be published. Required fields are marked *